NCT03808870View on ClinicalTrials.gov

A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 28, 2018

Primary Completion Date

February 12, 2022

Study Completion Date

February 16, 2022

Conditions

Malignant Neoplasm

Interventions

DRUG

NBM-BMX softgel capsules

Patients will initially receive NBM-BMX orally once a day at 100 mg per day.

Trial Locations (2)

112

Taipei Veterans General Hospital, Taipei

704

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors

lead

NatureWise Biotech & Medicals Corporation

INDUSTRY

NCT03808870 - A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter